HEMATOLOGIC ONCOLOGY--DRUG DEVELOPMENT AND TESTING

血液肿瘤学——药物开发和测试

• 批准号: 6101347
• 负责人: DAVID W GOLDE
• 金额: $ 18.86万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-01 至 2001-07-05
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6101347
• 关键词: acute leukemia; antileukemic agent; biological response modifiers; biomarker; bone marrow transplantation; chronic leukemia; clinical trials; colony stimulating factor; combination cancer therapy; drug design /synthesis /production; drug screening /evaluation; hematopoietic growth factor; hematopoietic stem cells; human subject; human therapy evaluation; leukemia; minimal residual disease; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; nonHodgkin's lymphoma; polymerase chain reaction; remission /regression; statistics /biometry

The overall aim of the Hematologic Oncology Project is to develop and test new and effective strategies for treating hematologic neoplasms using dose-intense approaches and biologic therapies. The Specific Aims are: 1. To test novel dose-intense strategies for treating non-Hodgkin's lymphoma and myeloma with growth factor and stem cell support, and monitoring of minimal residual disease (Projects 2-1, 2-2, 2-3). 2. To develop and test a curative intent treatment for chronic lymphocytic leukemia with assessment of minimal residual disease (Project 2-3). 3. To develop new biologic therapies for hematologic neoplasia (Project 2- 7). Project 2-1 focuses on the development and application of a clonotypic PCR for monitoring of minimal residual disease and Project 2-2 examines a dose-intense approach to relapsed lymphoma with stem cell mobilization. Project 2-3 proposes a curative intent protocol for chronic lymphocytic leukemia with PCR determination of minimal residual disease. Project 2-4 examines a therapeutic approach to poor-risk acute myelogenous leukemia integrating chemotherapy concomitant with colony-stimulating factor treatment. Project 2-5 examines new chemotherapeutic and differentiating agents in hematologic oncology. These projects follow the overall themes of the Program Project grant and integrate closely with the Solid Tumor Oncology Program.

血液肿瘤学项目的总体目标是开发和测试 治疗血液肿瘤的新的有效策略， 剂量密集的方法和生物疗法。 具体目标是： 1.为了测试治疗非霍奇金淋巴瘤的新剂量密集策略， 淋巴瘤和骨髓瘤伴生长因子和干细胞支持，和 监测微小残留病（项目2-1、2-2、2-3）。 2.开发和测试慢性淋巴细胞性白血病的治愈性治疗， 白血病与微小残留病评估（项目2-3）。 3.为血液肿瘤开发新的生物疗法（项目2- 7）。 项目2-1的重点是克隆型PCR的开发和应用 用于监测微小残留病，项目2-2检查了 干细胞动员治疗复发性淋巴瘤的剂量密集方法。 项目2-3提出了一种治疗慢性淋巴细胞性白血病的治疗方案。 白血病微小残留病PCR检测 项目2-4 探讨了低风险急性髓细胞白血病的治疗方法 联合化疗与集落刺激因子 治疗 项目2-5研究新的化疗和分化 血液肿瘤学药物。 这些项目遵循总的主题 与实体肿瘤紧密结合 肿瘤学项目。